Bengali
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Effect of Indian Gooseberry Extract (AMX160) in Hypercholesterolemia

কেবল নিবন্ধিত ব্যবহারকারীরা নিবন্ধগুলি অনুবাদ করতে পারবেন
প্রবেশ করুন - নিবন্ধন করুন
লিঙ্কটি ক্লিপবোর্ডে সংরক্ষিত হয়েছে
স্থিতিনিয়োগের
স্পনসর
Arjuna Natural Limited

কীওয়ার্ডস

বিমূর্ত

This study evaluates the efficacy of a fresh fruit extract of Indian Gooseberry (AMX160) for the attenuation of increased blood cholesterol, LDL cholesterol and triglycerides in patients with hypercholesterolemia.

বর্ণনা

Phyllanthus emblica L. fruit (Emblica officinalis) has potent antioxidant properties. Animal studies indicate that flavanoids from E. officinalis effectively reduced lipid levels in serum and tissues and had a significant inhibitory effect on hepatic hydroxymethylglutaryl-coenzyme A reductase activity.

The primary aim of this study is to determine whether Phyllanthus emblica L. fruit extract AMX160 is an effective treatment for hypercholesterolemia patients as compared to placebo. The investigators hypothesize that Phyllanthus emblica L. fruit extract AMX160 will significantly lower the total cholesterol as compared to placebo in patients with Hypercholesterolemia. A total of 132 patients including males and females with hypercholesterolemia will be assigned at random to one of the two investigational products. The study is expected to have a treatment duration of 90 ± 10 days and a total duration of 118 days including 14 days of grace period and 14 days of screening period per patient.

তারিখ

সর্বশেষ যাচাই করা হয়েছে: 12/31/2018
প্রথম জমা দেওয়া: 03/20/2018
আনুমানিক তালিকাভুক্তি জমা দেওয়া হয়েছে: 03/20/2018
প্রথম পোস্ট: 03/26/2018
সর্বশেষ আপডেট জমা দেওয়া হয়েছে: 01/08/2019
সর্বশেষ আপডেট পোস্ট: 01/09/2019
আসল অধ্যয়ন শুরুর তারিখ: 06/03/2018
আনুমানিক প্রাথমিক সমাপ্তির তারিখ: 04/30/2019
আনুমানিক অধ্যয়ন সমাপ্তির তারিখ: 07/31/2019

অবস্থা বা রোগ

Hypercholesterolemia

হস্তক্ষেপ / চিকিত্সা

Dietary Supplement: AMX160

Dietary Supplement: Placebo

পর্যায়

-

বাহু গ্রুপ

বাহুহস্তক্ষেপ / চিকিত্সা
Experimental: AMX160
500 mg (one capsule) x 2 times daily for 90 days
Dietary Supplement: AMX160
500 mg Phyllanthus emblica L. fresh fruit extract capsules
Placebo Comparator: Placebo
500mg (one capsule) x 2 times daily for 90 days.
Dietary Supplement: Placebo
500 mg roasted rice powder in visually identical capsules

যোগ্যতার মানদণ্ড

বয়স অধ্যয়নের জন্য যোগ্য 18 Years প্রতি 18 Years
লিঙ্গ অধ্যয়নের জন্য যোগ্যAll
স্বাস্থ্যকর স্বেচ্ছাসেবীদের গ্রহণ করেহ্যাঁ
নির্ণায়ক

Inclusion Criteria:

- 1. Males and females aged 18 to 65 years with hypercholesterolemia symptoms: blood Triglycerides, >200 mg/dL, blood cholesterol >200 mg/dL, blood LDL cholesterol >130 mg/dL

Other requirements for inclusion in the study are:

2. Moderate-intensity physical activity (less than 150 minutes or less than 75 minutes of vigorous-intensity physical activity throughout the week) 3. No medication taken for management of hypercholesterolemia during last 4 weeks.

4. Ability to understand and provide signed informed consent. 5. Ability to participate in the study.

Exclusion Criteria:

1. Uncontrolled cardiovascular disease or advanced atherosclerosis (e.g. history of stroke, myocardial infarction, life- threatening arrhythmia, or coronary revascularization within the preceding 6 months; unstable angina; congestive heart failure; known or suspected clinically significant valvular heart disease or uncontrolled hypertension (>160/100 mm of Hg or use of antihypertensive medications, dose of which is not stable in the last one month)

2. Very high triglyceride levels i.e. > 500 mg/dL

3. Diabetes (Fasting Blood Sugar>150 mg/dL), using insulin, glitazones , another hypoglycemic dose of which is not stable in last one month

4. Pregnancy, lactation and female patients not using acceptable contraceptive measures (double barrier methods, oral or injectable hormonal contraceptives or surgical sterilization)

5. Hepatic impairment (Alanine transaminase or Aspartate transaminase levels > 3.0 mg/dl Upper Limit of Normal (ULN)) or renal impairment (serum creatinine≥ 2.0 mg/dl)

6. Severe systemic illness and in the opinion of the investigator would be noncompliant with the visit schedule or study procedures

7. Known history of hypersensitivity to Indian Gooseberry or any product containing Indian Gooseberry extract

8. Patients with history of alcohol intake (For females >3 drinks / day or >7 drinks / week. For Males >4 drinks/ day or > 14 drinks / week).

9. Patients taking any narcotics and prohibited substances.

10. Serious concurrent illness or malignancy.

11. Agreements of participation in another clinical trial in the past 3 months

12. Two of the following risk factors:

1. Cigarette smoking (Current / Previous smoker < 1 yr)

2. Hypertension (BP >140/90 mmHg or on antihypertensive medication)

3. Low HDL cholesterol (<40 mg/dL)

4. Family history of premature CHD (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years).

ফলাফল

প্রাথমিক ফলাফল ব্যবস্থা

1. Change in Total Cholesterol [Baseline, Day 45 & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

মাধ্যমিক ফলাফলের ব্যবস্থা

1. Change in Triglycerides [Baseline, Day 45 & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

2. Change in Low Density Lipoprotein Cholesterol [Baseline, Day 45 & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

3. Change in High Density Lipoprotein Cholesterol [Baseline, Day 45 & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

4. Change in Very Low Density Lipoprotein Cholesterol [Baseline, Day 45 & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

5. Change in Triglyceride /High Density Lipoprotein Cholesterol ratio [Baseline, Day 45 & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

6. Change in Apolipoprotein A-1 [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

7. Change in Apolipoprotein B [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

8. Change in Apolipoprotein B/Apolipoprotein A-1 Ratio [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

9. Change in hydroxymethylglutaryl-coenzyme A [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

10. Change in Coenzyme Q10 [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

11. Change in Atherogenic index of Plasma [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

12. Change in Adult Treatment Panel III goal (Triglyceride < 150 mg/dL, LDL < 100 mg/dL, HDL > 40) [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

অন্যান্য ফলাফলের ব্যবস্থা

1. Change in Thyroid-stimulating hormone [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

2. Change in Homocysteine [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

3. Change in High Sensitivity C-Reactive Protein [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

4. Change in Global Physical Activity Questionnaire [Baseline & Day 90]

The change over time from the baseline to end of treatment, both within and between the group.

আমাদের ফেসবুক
পেজে যোগদান করুন

বিজ্ঞানের দ্বারা সমর্থিত সবচেয়ে সম্পূর্ণ completeষধি ভেষজ ডেটাবেস

  • 55 ভাষায় কাজ করে
  • বিজ্ঞানের সহায়তায় ভেষজ নিরাময়
  • ইমেজ দ্বারা ভেষজ স্বীকৃতি
  • ইন্টারেক্টিভ জিপিএস মানচিত্র - অবস্থানের উপর গুল্ম ট্যাগ করুন (শীঘ্রই আসছে)
  • আপনার অনুসন্ধান সম্পর্কিত বৈজ্ঞানিক প্রকাশনা পড়ুন
  • তাদের প্রভাব দ্বারা herষধি গুল্মগুলি অনুসন্ধান করুন Search
  • আপনার আগ্রহগুলি সংগঠিত করুন এবং নিউজ রিসার্চ, ক্লিনিকাল ট্রায়াল এবং পেটেন্টগুলির সাথে আপ ডেট থাকুন

একটি লক্ষণ বা একটি রোগ টাইপ করুন এবং এমন গুল্মগুলি সম্পর্কে পড়ুন যা সহায়তা করতে পারে, একটি bষধি টাইপ করতে পারে এবং এর বিরুদ্ধে ব্যবহৃত রোগ এবং লক্ষণগুলি দেখতে পারে।
* সমস্ত তথ্য প্রকাশিত বৈজ্ঞানিক গবেষণার উপর ভিত্তি করে

Google Play badgeApp Store badge